

REVIEW ARTICLE

Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group

E. R. Gomes¹, K. Brockow², S. Kuyucu³, F. Saretta⁴, F. Mori⁵, N. Blanca-Lopez⁶, H. Ott⁷, M. Atanaskovic-Markovic⁸, M. Kidon⁹, J.-C. Caubet¹⁰ & I. Terreehorst¹¹ on behalf of the ENDA/

1 EAACI Drug Allergy Interest Group

¹Allergology Department, Centro Hospitalar do Porto, Porto, Portugal; ²Division Environmental Dermatology and Allergology Helmholtz Zentrum München/TUM, Department of Dermatology und Allergologie Biederstein, Technical University Munich, Munich, Germany; ³Department of Pediatric Allergy and Clinical Immunology, Faculty of Medicine, Mersin University, Mersin, Turkey; ⁴Pediatric Department, Hospital of Palmanova, A.S.S.5 'Bassa Friulana', Palmanova UD; ⁵Allergy Unit, Department of Pediatric, Anna Meyer Children's Hospital, University of Florence, Florence, Italy; ⁶Allergy Department, Infanta Leonor University Hospital, Madrid, Spain; ⁷Division of Pediatric Dermatology, Children's Hospital Auf der Bult, Hannover, Germany; ⁸University Children's Hospital of Belgrade, Medical Faculty University of Belgrade, Belgrade, Serbia; ⁹Allergy and Clinical Immunology Unit and Institute for Pediatric Pulmonology and National CF Center, Safra Children's Hospital, Tel Hashomer, Israel; ¹⁰Division of Pediatric Allergy, University Hospital of Geneva, Geneva, Switzerland; ¹¹Department

2 of ENT and Pediatrics, AMC, Amsterdam, The Netherlands

To cite this article: Gomes ER, Brockow K, Kuyucu S, Saretta F, Mori F, Blanca-Lopez N, Ott H, Atanaskovic-Markovic M, Kidon M, Caubet J-C, Terreehorst I on behalf of the ENDA/EAACI Drug Allergy Interest Group. Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group. *Allergy* 2015; DOI: 10.1111/all.12774.

Keywords

children; drug allergy; drug hypersensitivity; task force report.

Correspondence

Eva Rebelo Gomes, Allergology Department, Centro Hospitalar do Porto, Porto, Portugal.
Tel.: +351-222-077-500
Fax: +351-222-053-218
E-mail: evamariasrg@yahoo.com

Accepted for publication 21 September 2015

DOI:10.1111/all.12774

Edited by: Pascal Demoly

Abstract

When questioned, about 10% of the parents report suspected hypersensitivity to at least one drug in their children. However, only a few of these reactions can be confirmed as allergic after a diagnostic workup. There is still a lack of knowledge on drug hypersensitivity (DH) epidemiology, clinical spectrum, and appropriate diagnostic methods particularly in children. Meanwhile, the tools used for DH management in adults are applied also for children. Whereas this appears generally acceptable, some aspects of DH and management differ with age. Most reactions in children are still attributed to betalactams. Some manifestations, such as nonsteroidal anti-inflammatory drug-associated angioedema and serum sickness-like reactions, are more frequent among young patients as compared to adults. Risk factors such as viral infections are particularly frequent in children, making the diagnosis challenging. The practicability and validity of skin test and other diagnostic procedures need further assessment in children. This study presents an up-to-date review on epidemiology, clinical spectrum, diagnostic tools, and current management of DH in children. A new general algorithm for the study of these reactions in children is proposed. Data are presented focusing on reported differences between pediatric and adult patients, also identifying unmet needs to be addressed in further research.

Abbreviations

ADR, adverse drug reactions; AGEP, acute generalized exanthematous pustulosis; BAT, basophil activation test; BL, betalactams; DH, drug hypersensitivity; DHR, drug hypersensitivity reactions; DPT, drug provocation test; DRESS, drug reaction with eosinophilia and systemic symptoms; EAACI, European Academy of Allergy and Clinical Immunology; ENDA, European Network for Drug Allergy; GRADE, Grading of Recommendations Assessment, Development, and Evaluation; HIV, human immunodeficiency virus; IDT, intradermal test; LTT, lymphocyte transformation test; MPE, maculopapular exanthema; NMBA, neuromuscular blocking agents; NSAID, nonsteroidal anti-inflammatory drug; RCM, radiocontrast media; SCARs, severe cutaneous adverse reactions; SJS, Stevens–Johnson syndrome; SPT, skin prick test; SSLR, serum sickness-like reaction; TEN, toxic epidermal necrolysis.

When questioned, about 10% of the parents report suspected hypersensitivity to at least one drug in their children (1–5).

However, after a full allergy workup, only a few of the suspected reactions can be confirmed as drug hypersensitivity reactions (DHR) (1, 2).

The drugs prescribed and involved in adverse drug reactions (ADR) and in DH differ between children and adults (6, 7). In the pediatric population, betalactam (BL) antibiotics are the most commonly involved drug group followed by nonsteroidal anti-inflammatory drugs (NSAIDs) and non-BL antibiotics (1–5, 8).

Clinical presentations are diverse, ranging from maculopapular and nonimmediate urticarial exanthemas to life-threatening reactions, such as anaphylaxis and severe cutaneous adverse reactions (SCARs).

Risk factors, comorbidities, and differential diagnoses are age dependent. For instance, viral and bacterial infections with exanthemas, important differential diagnoses for DH, are much more common in young children (9–12).

Traditionally, the same diagnostic algorithms and techniques are used for children and adults, assuming that the general principles applied for adults are also applicable in children. The use of skin tests poses special problems. Particularly, intradermal tests (IDTs), which are more sensitive than prick tests, are painful and can be poorly tolerated by small children. Thus, for nonimmediate reactions, such as mild exanthemas, it has been proposed to perform drug provocation tests (DPT) without prior skin tests (13–16).

Suitable pediatric therapeutic alternatives are lacking for many drugs. For instance, after DHRs to BL and NSAIDs, lifelong avoidance as practiced often in adults is more difficult in children.

This consensus paper of the European Network for Drug Allergy (ENDA) and the EAACI Drug Allergy Interest Group is the result of a task force on pediatric DH, aiming to present an up-to-date review of the available information regarding DH in children with a focus on differences compared to adult patients, to propose a general diagnostic algorithm, and to address controversial issues and unmet needs as well as areas for future investigation.

4 Methods

Data sources

Articles in English, German, Italian, French, Portuguese, and Spanish with data on DH in children were identified by searching the databases of MEDLINE (National Library of Medicine) from January 1990 till December 2013. Additional articles were retrieved from archives and reference lists of the identified articles. The experience/expertise of the members of the Task Force panel was considered. We included observational studies, case series, case reports, and personal experience of the members of the group, when another reliable data were lacking. We focused on commonly involved drugs in children, that is, antibiotics, NSAIDs, radiocontrast media (RCM), perioperative, and chemotherapeutics drugs. Of note,

hypersensitivity to vaccines will not be discussed in this study, as this is the aim of other ongoing Task Force.

Data extraction and quality grading

The relevance of the articles was evaluated by the authors on the basis of their titles and abstracts. Selected articles were then retrieved, analyzed, and interpreted. For each statement, the quality of evidence and recommendation was graded and discussed by the Task Force members, confirmed, or amended by consensus of the group. Grading for key statements was performed using the GRADE system. Evidence was graded as high, low, or very low. The strength of the recommendations was strong or weak, that is, the grading of low/strong in the text denotes a low quality of evidence and strong strength of recommendation (17).

Epidemiology of drug hypersensitivity in children

Adverse drug reactions consist of any undesired effects that appear in the course of the clinical use of a drug (18). These reactions have been traditionally classified into the following: type A reactions (predictable by the known intrinsic properties of the drug, which include most of the toxic side-effects) and type B reactions (less dose dependent, unpredictable, and corresponding to either allergic or nonallergic hypersensitivity reactions). The term ‘drug allergy’ is used specifically when immunological mechanisms have been demonstrated (19).

In children, as well as in adults, most epidemiologic studies usually include both types, with a large predominance of type A reactions, which makes it difficult to estimate the prevalence of DH. The reported incidence of ADRs in the pediatric population is generally considered lower as compared to adults. Nevertheless, a recent systematic review of published data on ADRs in children showed that from 0.4% to 10.3% of all pediatric hospital admissions can be ADR-related (2.9% overall incidence) and that 0.6% to 16.8% of all children exposed to a drug during hospital stay can suffer an ADR (20).

These data confirm that ADRs constitute an important medical and public health problem among children (21).

The drugs most commonly reported in association with ADRs, the prescriptions, and the therapeutic options in children may differ from those in adults (weak) (6, 7).

Accurate epidemiological data on DH in general, and particularly in children, are virtually lacking (high). However, some studies indicate that among ADR, DH in children may be more common compared to adults: more than 50% of ADRs among pediatric inpatients and about 35% of ADRs in emergency department visits are supposedly allergic (very low) (6, 22, 23).

Drug hypersensitivity is perceived as an important problem in adults as well as in children (high). When questioned, up to 25% of the general adult population (24) and as much as 10% of parents report their children to be allergic to drugs, with BL antibiotics being the most frequently suspected (1–5). However, the clinical investigation of suspected reactions shows that these numbers are overvalued (high) (1, 2, 25).

Community-based studies and self-reporting generally lead to an overestimation of the rates of DH and drug allergy.

The prevalence of self-reported DH is higher in adults, and it generally increases with age (26, 27).

A Spanish study addressing the reasons for patient referral to allergy departments showed that the suspicion of drug allergy is the third cause, after asthma and rhinitis. It represents 15% of the referrals among adults and 9.8% in children. Betalactams allergy was the motive for referral in 81% of the pediatric cases, but it was suspected in only 47% of the reactions in adults. On the other hand, hypersensitivity to NSAIDs was more frequently reported among adults (24%) than children (13%) (8).

Risk factors and differential diagnosis

Young children appear to be at increased risk for ADRs, when compared to older children (low) (21, 23, 28, 29). The risk increases with the number of drugs taken and off-label prescriptions (low) (21, 29–32). Adverse drug reactions are generally considered to be more common in children with cystic fibrosis, potentially explained by higher levels of exposition to drugs, frequent use of intravenous drugs, and specific immune responses related to cystic fibrosis itself (33). However, a recent study based on systematic full allergic workup showed that although the frequency of proven BL hypersensitivity is high in children with CF, the global prevalence of BL hypersensitivity is lower in children with CF compared to the general pediatric population. These data need to be confirmed by large prospective studies (34). Although an increased risk has been associated with the female gender, particularly for perioperative reactions, this gender pattern has not been documented among children (low) and the age/gender pattern for suspected DH is similar to the one for viral infections (35, 36).

Infections are common in children, particularly viral ones, and are risk factors or differential diagnoses to DH (high). Most of the skin rashes occurring during BL treatment have been suggested to be due to the infection itself, and DH has been confirmed in <10% of the cases (high) (13, 25, 37, 38).

Underlying viral infections may also act as cofactors in susceptible individuals (low) (39).

In children, aminopenicillins may induce an exanthema especially in patients with Epstein–Barr virus infection, although the incidence is lower than originally reported (40, 41).

HHV-6 reactivation may be a cofactor in drug reaction with eosinophilia and systemic symptoms (DRESS) (42–44). DH is also more common in patients with cytomegalovirus and human immunodeficiency virus (HIV) infection (high) (45, 46).

Atopy, asthma, and chronic urticaria were reported to be significant risk factors for reactions to NSAIDs in children (low) (47–52).

Main elicitors/drugs

Antibiotics

In children, the suspicion of BL allergy is the most common reason for referral to the drug allergy consultation (high) (8).

Adverse drug reactions in pediatric patients were reported to be caused in 45% by BL and in 23% by non-BL antibiotics. The estimated prevalence of DH to BL ranges from 1% to 10% (very low) (1, 2, 10, 26, 53).

Macrolides and sulfonamides are also frequently involved, but rarely confirmed in pediatric DHRs (low). The prevalence is closely linked to different prescription habits in different countries (54–56).

Among children, the reported macrolide allergy prevalence ranges from 0.07% to 0.7%, with most reactions being mild cutaneous exanthemas (very low) (3–5, 26).

Suspected allergy to sulfonamide antibiotics in children was reported to range from 0.2% to 2.2% for different age groups (3–5, 26) with the exception of one prospective study reporting an incidence of sulfonamide antibiotic-associated rash of 8.5% among outpatient children (low) (10).

Children infected with HIV have an increased risk of cutaneous reactions from sulfonamide antibiotics, some of which can be very severe (high) (57–59).

Hypersensitivity reactions to quinolones, vancomycin, aminoglycosides, and tetracyclines are rarely reported, partly because of the limited prescription of these drugs in children, except in particular populations, such as cystic fibrosis patients (low) (3–5, 10, 26, 53, 60).

Nonsteroidal anti-inflammatory drugs and analgesics

Nonsteroidal anti-inflammatory drug hypersensitivity in children has not been sufficiently studied. The most commonly used drugs in children are ibuprofen and paracetamol. Drug hypersensitivity to NSAIDs in some adult populations occupies now the first place among self-reported DH (61).

The prevalence is lower among children; however, NSAIDs rank second among drugs suspected to cause DH in pediatric patients (1–5).

Cutaneous and respiratory reactions are the most common manifestations (low). In a study enrolling more than 27 000 children <2 years old, treated with ibuprofen and paracetamol for an acute febrile illness, no hospitalizations occurred secondary to acute anaphylaxis (62). Older studies report a questionnaire-based frequency of NSAID-induced reactions of 0.32% (2 of 618) in children (63).

An increasing rate of NSAID hypersensitivity has been observed with increasing age among consulting atopic children. The estimated rate in this population was 4%, and the most common clinical manifestation was isolated facial and periorbital edema (64).

In a systematic review on prevalence of aspirin-induced asthma, challenge-confirmed ASA hypersensitivity in asthmatic children and adults was estimated to be 5% (0–14%) and 21% (14–29%), respectively (65).

Nonsteroidal anti-inflammatory drugs are known to aggravate chronic urticaria in adults (high), whereas specific data in children are mostly lacking (63). Other cutaneous manifestations include fixed drug eruptions, photosensitivity, and SCARs. In fact, NSAIDs are among the drugs most frequently associated with Stevens–Johnson syndrome (SJS) in children (66, 67).

Perioperative drugs

The study by DeWachter et al. (68) reports an overall incidence for perioperative anaphylaxis in the pediatric population of one in 7741 anesthetic procedures. Rates appear to be higher in selected populations, as in children with congenital malformations, submitted to several interventions (low) (69). In contrast to adults, neuromuscular blocking agents (NMBAs) are less commonly incriminated in children, with an estimated incidence at one in 80 000 anesthetic procedures being the second leading cause after latex in this setting (35). Anaphylaxis due to induction agents is rare (low).

Radioccontrast media

The overall reported incidence of immediate reactions to intravenous nonionic iodinated RCM in children is lower than in the adult population. In the large study by Katayama et al., DHR with severe cardiovascular or respiratory involvement has been reported with an incidence of 0.07% for nonionic contrast media in children aged 1–19 years (70). Other large studies have reported incidences of 0.18% (20 of 11 306) and 0.46% (57 of 12 494) for all DHR (71–73). Gadolinium-containing contrast media were associated with DH reactions in 0.04% of the pediatric patients (74–76).

Chemotherapeutics drugs

Carboplatin and asparaginase are frequent causes of DH among treated children. Drug hypersensitivity to carboplatin is associated with repetitive therapeutic courses (77–79). In one review on children affected by low-grade glioma, 44 of 105 children (42%) developed hypersensitivity to carboplatin (78). Seventeen (9.2%) of the 185 children, affected by different solid tumors and treated with etoposide–carboplatin, presented an allergic reaction to carboplatin: 2% at 6 courses, 11% at 12 courses, and 47% at more than 12 courses (79). Hypersensitivity reactions to asparaginase have been reported in up to 40% of the treated children (80, 81). Incidence seems to depend on the different types of asparaginase preparations, the regimens used, and the route of administration (82, 83). Reports about DHR due to other chemotherapeutic drugs are sparse.

Clinical manifestations of drug hypersensitivity in children

Dermatological presentations

Maculopapular exanthema (MPE) is considered to be the most common skin reaction (low) (84). Maculopapular exanthema and nonimmediate urticarial exanthemas are particularly observed in children treated with BL (high) and further to non-BL antibiotics, NSAIDs, and nervous system medication (85, 86). Immediate cutaneous reactions such as urticaria, pruritus, and erythema are also frequently attributed to BL antibiotics, sulfonamides, NSAIDs, and NMBAs (low) (86). Regarding DH to NSAIDs, facial angioedema

manifests in <5% of infants and toddlers, but in up to 20% of adolescents and young adults (very low). More than 80% of hypersensitive children may cross-react upon challenge with another NSAID (very low) (51, 87–89).

Fixed drug eruption in children has mostly been associated with sulfonamides, and rare reports are found concerning other antibiotics, NSAIDs, and antihistamines (low) (90, 91).

Far less common cutaneous reactions in children include DRESS, acute generalized exanthematic pustulosis (AGEP), and SJS/toxic epidermal necrolysis (TEN). DRESS is reported to occur in approximately 1 : 1000 to 1 : 10000 of exposures to aromatic anticonvulsants, which are the most frequent cause (low). Drugs such as allopurinol, antibiotics, aspirin, and lamotrigine have been less frequently implicated in pediatric DRESS (92–98).

Acute generalized exanthematous pustulosis has been observed in children treated with BL, but also with other drugs and in the course of viral and bacterial infections (97–103). Regarding SJS/TEN, a pooled analysis of medications in 80 pediatric patients (<15 years) and 216 matched controls showed that sulfonamides, anticonvulsants, paracetamol, and NSAIDs were frequent culprit medications (low) (66).

Respiratory presentations

Symptoms include either isolated respiratory reactions (mostly restricted to NSAIDs) or, more frequently, respiratory symptoms as part of an anaphylactic reaction (low) (104). The risk is higher among asthmatic children (low). Delayed respiratory hypersensitivity reactions, such as drug-induced pneumonitis, are rare in children with any type of medication except chemotherapeutic drugs (low).

Anaphylaxis

In a recent review, Hompes et al. (105) reported that DH was the cause of anaphylaxis in 8% of children. There is insufficient data on the culprit drugs, but there is no reason to believe that the situation would be different from adults, where BL and NSAIDs are the most common triggers (very low) (106).

Serum sickness-like reactions

Serum sickness-like reaction (SSLR) is uncommon and mostly restricted to young children (107).

Cefaclor has been the major culprit drug, with an estimated incidence of 0.024% in controlled trials and 0.5% in published reports, but other BL have been increasingly implicated (16, 108–113). Trimetoprim–sulfamethoxazole administration has a reported SSLR incidence of 5 per 5597 courses of treatment (108).

Diagnostic approach to drug hypersensitivity in children

The main differential diagnosis of DH in children is a viral infection. The diagnosis relies on a complete allergy workup, ideally performed 1–6 months after complete recovery of the

initial reaction (low, strong) (Fig. 1). The diagnostic methods for pediatric patients are the same as for adults and consist of clinical history, skin tests, laboratory tests (if available and validated), and DPTs (strong).

Clinical history

The diagnostic workup should start with a complete and precise clinical history (114).

The history is often taken from the caregivers, which may lead to inaccurate or exaggerated pictures. Difficulties may also arise from the fact that children are generally less able to express themselves. The use of photos (e.g., by cell phone)

to get a better description of the skin lesions at the acute phase should be encouraged as well as searching for danger signs as is advised in adults (115).

Skin tests

Skin tests include skin prick test (SPT), IDT, and patch tests. Regarding their diagnostic value, few pediatric studies have been published so far (Table 1) (13, 37, 113, 116–121). Published limitations and contraindications of skin testing in adults also apply for children (122).

Skin tests with drugs are considered relatively safe in children, with a reported rate of systemic reactions ranging




Figure 1 Algorithm for the diagnosis of immediate and nonimmediate drug hypersensitivity in children.

Table 1 Summary of studies including only children on the diagnosis of immediate and/or nonimmediate drug hypersensitivity to antibiotics

Authors	No. of patients	No. of patients with positive results (%) Immediate reactions	No. of patients with positive results (%) Nonimmediate reactions	No. of patients with positive results (%) Not specified
Betalactams				
Pichichero & Pichincher (116)	247	84 (34)	20 (8.1)	
Ponvert et al. (113)	325	24 (7.4)	15 (4.6)	
Atanaskovic-Markovic et al. (117)	1170	682 (58.3)		
Romano et al. (118)	148	34 (79) of 43	1 (0.9) of 105	
Ponvert et al. (37)	1431	50 (30.9) of 162	177 (16.7) of 1087	227 (15.9)
Atanaskovic-Markovic et al. (119)	245	14 (43.7) of 32	19 (59.4) of 32	32 (13)
Caubet et al. (13)	88	6 (6.8)		
Macrolides				
Mori et al. (120)	64	14 (21.8)		
Atanaskovic-Markovic et al. (119)	115	1 (0.8)	2 (1.7)	
Sulfonamides				
Adegbidi et al. (121)	21			11 (52.38)
Atanaskovic-Markovic et al. (119)	37	1 (2.7)	5 (13.5)	

between 0.3% and 1.2%; no fatalities among children could be found in the literature (13, 37, 123).

However, skin tests, especially IDT, are painful and less tolerated by children. Thus, in a query among ENDA members, 8 of 11 responders (73%), experienced with both adults and children, declared to use less IDT in children (unpublished data).

Skin tests in DH have been mainly standardized in adult populations, and test accuracy can only be extrapolated from mixed adult/pediatric studies (Table 2) (124). As there are no specific guidelines for children, general recommendations for adults have been applied (122, 125).

Due to the paucity of reliable data, it is difficult to assess the real value of skin tests to drugs in children, because most publications reporting skin test results are older, have neither used actual recommended protocols, nor have included DPTs and have validated their results only against the clinical history. Recent reports showed that the evidence to date does not clearly lean in favor or against skin testing in children (126–128).

Table 2 Level of certainty to recommend skin tests in children with suspected drug hypersensitivity

Higher evidence	Lower evidence
Anticonvulsants	Biologicals
Betalactam antibiotics*	Local anesthetics
Chlorhexidine*	Hormones
Heparins	Insulins
Neuromuscular blocking agents*	Nonbetalactam antibiotics
Platinum salts	Nonpyrazolone NSAIDs
Radiocontrast media	Opioids
Blue dyes	
Proton pump inhibitors	

*In addition, specific IgE determinations are available and recommended for these drugs.

It is also impossible to say whether test concentrations that are currently used are also optimal for children (very low) and there are some publications recommending different concentrations especially for cephalosporins (117, 129, 130).

However, the limited number of available studies indicates that using the same concentrations in similar clinical settings, the sensitivity seems to be comparable for adults and children (131–133).

Most of the studies focusing on pediatric patients evaluating the performance of skin tests concern antibiotics (Table 1). While the diagnostic value of those tests (SPT and IDT) is relatively high for immediate reactions (meaning reactions occurring up to one hour after drug administration) mainly concerning BL, several recent pediatric studies have confirmed a low sensitivity of skin tests (IDT and/or patch tests) to diagnose nonimmediate hypersensitivity in children (13, 14, 16, 25, 37, 134, 135).

Patch tests have been suggested to be especially useful to diagnose nonimmediate hypersensitivity to anticonvulsants and NSAIDs, but further large studies are needed to evaluate their diagnostic value (38, 119, 136).

In vitro testing

Due to the lack of sufficient comparative data, the same general principles and rules are considered applicable for both children and adults, although there is a considerably less available experience in children. The most commonly applied procedure is quantification of IgE antibodies, mainly relevant for BL, particularly the benzyl penicilloyl and the amoxicilloyl determinants. However, sensitivity is limited and comparison of commercial tests versus in house-produced tests indicates important differences in sensitivity (low) (137). In severe anaphylactic reaction involving BL antibiotics or NMBA, specific IgE measurement for the suspected culprits and cross-reactive drugs is recommended by some authors before skin testing if available. The rest of commercial available drugs for quantifi-

cation of IgE antibodies are other low molecular weight compounds such as penicilloyl V, ampicilloyl, cefaclor, chlorhexidine, suxamethonium, morphine and pholcodin, or protein/polymers like insulin, bovine gelatin, adrenocorticotrophic hormone, protamine, tetanus toxoid, and chymopapain.

Additional tests, such as basophil activation test (BAT), measurement of sulfidoleukotrienes, the lymphocyte transformation test (LTT), and the ELISPOT assay, have predominantly been used in adults, and the value in children cannot be estimated (very low) (138, 139).

The BAT and sulfidoleukotriene release test may be applied when specific IgE to a drug is negative or not available, although only small series have been reported (weak) (139–141).

Most of the validated data exist on BL antibiotics in adults, where the reported sensitivity of the BAT is <60% (142).

Lymphocyte transformation test may be applied for the diagnosis of nonimmediate allergic drug reactions (weak), but the test has mostly been used in research settings (to explore the involved immunological mechanisms) rather than in clinical practice (143–146).

The ELISPOT assay applied to the diagnosis of drug allergy is based on the quantification of cytokines or other T-/B-cell products in peripheral blood. There are studies for T-cell-dependent reactions. In cases with MPE and Steven-Johnson reactions, it has been shown that this procedure is more sensitive than the classical LTT assay (147, 148). Particularly, the combination of the quantification of more than one cytokine and other proteins such as granzyme B provides a higher sensitivity (148). However, overall the number of cases evaluated is rather small and more studies are needed to confirm these data.

Drug provocation tests

Provocation tests are particularly important in children, as the main culprits (i.e., BL antibiotics, ibuprofen and paracetamol) will often be needed again in future treatments, and in many cases, DH cannot be excluded by other means. General recommendations for DPT, including indications and contraindications, also apply for children (149).

Many schemes for DPT in children have been proposed, and the optimal protocol is debatable. First, for each child, the therapeutic single and daily dose has to be calculated according to age/weight. As a general rule, we recommend to start with approximately 1/10 of a single dose and proceed to half and a full dose (weak). In severe reactions, a lower starting dose, sometimes as low as 1 : 10000 to 1 : 1000 of the maximum therapeutic dose, should be used (weak). The cumulative daily dose should not be exceeded. The intervals have to be chosen according to the time course of the clinical manifestations of the initial reaction and the drug involved. Various intervals for incremental doses have been described, ranging from 20 min to 1 week (150). For example, an interval of 30 min to 2 h is generally appropriate for immediate reactions, whereas for nonimmediate exanthemas, longer intervals may be considered (weak) (14, 15, 37, 123, 132, 133, 149, 151–154).

The aim of the DPT is to confirm or exclude a reaction or to find safe alternative treatments, in case of confirmed DH to the culprit drug. Whereas the risk for future reactions can be further reduced by giving a full daily dose, or even 3-, 5-, and 7-day administration, the members of the Task Force panel believe that exposing on full single therapeutic dose is sufficient for most cases (weak) (113, 151, 155, 156).

Drug provocation tests have been reported to have a good negative predictive value both in children and in adults (123, 157–159). Taking into account the difficulty of performing painful IDT in children and the low sensitivity of these skin tests in mild nonimmediate skin reactions, several investigators suggested a physician-supervised DPT without previous skin testing provided that the patient has been observed at the acute phase by an experienced physician who confirms that the reaction was not severe (13–16, 160).

Studies have shown that this approach in mild MPE or nonimmediate urticarial exanthemas has not been associated with severe reactions during DPT (low). Based on the available data and the experience of the members of the Task Force panel, a general diagnostic algorithm for DH evaluation in children is proposed (Fig. 1), where a DPT without previous ST in the case of nonimmediate reactions manifesting as mild cutaneous exanthemas (which are the most prevalent ones in childhood) can be considered (14, 15).

Provocation tests should be performed in a hospital setting under strict surveillance by a trained team according to the published guidelines (149). Of note, Ponvert et al. (37, 113) have performed prolonged challenge at home with exceedingly rare severe reactions in patients with a history of mild nonimmediate reactions during betalactam treatment. However, these data need to be confirmed in different populations in large prospective studies. An open oral DTP seems to be sufficient in most pediatric cases, and only a few studies refer to blinded placebo-controlled tests (weak) (13–16, 37, 48, 87, 117, 118, 151, 153, 161, 162).

The investigation of suspected reactions using the available methods allows the exclusion of DH in the vast majority of the suspected cases (25, 118, 151, 161–164).

Therapy

Avoidance of the culprit and cross-reactive drugs is the treatment of choice for DHR. In children, this may be more difficult to achieve, compared to adults, because the choice of alternative drugs is more limited (due to prescription restrictions). For example, BL antibiotics are the first-line treatment for most infections in children, and widely used antibiotic alternatives for adults, such as tetracyclines and quinolones, are contraindicated. The same applies to paracetamol and ibuprofen. COX-2 inhibitor use is limited by their delay of action and, moreover, they are not approved in infants/young children in most countries. In addition, 'lifelong avoidance' implies a stronger restriction in children as their expected lifespan is much longer compared to that of adults. In selected cases, desensitization can be considered, even though experience in children is more limited compared to adults (165, 166).

Unmet needs

High-quality epidemiologic data, with precise phenotyping and full allergy workup, are lacking in children. Thus, the incidence and prevalence of DH to specific drugs and for specific clinical manifestations is unknown. Studies comparing feasibility and validity of the adult DH diagnostic procedures in children are required; current practice is mostly extrapolating adult experience to pediatric populations with a very limited number of confirmatory studies. The available guidelines for drug allergy diagnosis for adults should be further evaluated in children, especially regarding sensitivity of skin tests and DPT. The development of commercially available sensitive laboratory tests would be of particular interest in pediatric settings, as in this population, pain and fear can limit the use of skin tests. It has to be further studied in which clinical manifestations the skin test may be avoidable before performing DPT. A test allowing distinguishing DH from infectious exanthemas would be helpful. Standardization of DPT in children is necessary, as there is a great diversity of protocols making it difficult to compare published results. An agreement on desensitization procedures in pediatric ages is also needed as sometimes therapeutical alternatives do not exist or are clearly less effective. Multicenter studies with standardized protocols for different drugs are required.

Conclusions

Drug hypersensitivity in children has a parent-reported prevalence of around 10%, with a much lower real prevalence, and a lower prevalence of confirmed DH as compared to adults.

Betalactams are the main drugs implicated in DH among children and the most common cause of concern.

Nonsteroidal anti-inflammatory drugs, non-BL antibiotics, perioperative drugs, anesthetics, RCM, and cytotoxic drugs are also frequently suspected. Atopy and infections are the most important risk factors to consider especially regarding reactions to NSAIDs and antibiotics.

The most common reactions are nonimmediate MPE and urticaria. Drugs are the third identified cause for anaphylaxis among children. Facial edema associated with NSAID hypersensitivity and SSLD appear to be quite specific for children. The diagnostic approach to DH diagnosis is based on our experience in adults, but its adequacy in children has to be further evaluated. For example, DPT without previous skin tests can be considered in children with

nonsevere maculopapular and nonimmediate urticarial exanthemas.

Acknowledgments

We thank Dr Claude Ponvert and Dr Anca Chiriac for the help in critically revising the article.

Author contributions

Eva Gomes contributed to conception of the review, general structure of the paper, analysis and writing on data concerning epidemiology and diagnostic provocation tests, general writing of the paper, diagnostic algorithm elaboration and approval, management of references, and chair of the Task force; Knut Brockow to general structure of the paper, analysis of data on skin manifestations, critical reviewing and evidence grading, and diagnostic algorithm approval; Semanur Kuyucu to acquisition, analysis, interpretation, and writing on data concerning main elicitors, critical reviewing, and diagnostic algorithm approval; Francesca Saretta to acquisition, analysis, interpretation, and writing on data concerning main elicitors, critical reviewing, and diagnostic algorithm approval; Francesca Mori to acquisition, analysis, interpretation, and writing on data concerning main elicitors, critical reviewing, and diagnostic algorithm approval; Natalia Blanca-Lopez to acquisition, analysis, interpretation, and writing about laboratory data and critical reviewing; Hagen Ott to acquisition, analysis, interpretation, and writing on data concerning cutaneous manifestations; Marina Atanaskovic-Markovic to acquisition, analysis, interpretation, and writing on data related to diagnostic tests, diagnostic algorithm elaboration and approval, and critical reviewing; Mona Kidon to acquisition, analysis, interpretation, and writing on data concerning NSAIDs and on respiratory manifestations, critical reviewing, and evidence grading; Jean-Christoph Caubet to acquisition, analysis, interpretation, and writing on data concerning risk factors and diagnostic provocations, diagnostic algorithm elaboration and approval, management of references, and critical reviewing; Ingrid Terreehorst to general structure of the paper, analysis on data regarding clinical manifestations and writing clinical manifestations section, diagnostic algorithm elaboration and approval, management of references, critical reviewing, and secretary of the Task force.

Conflicts of interest

The authors declare that they have no conflicts of interest.

References

1. Erkocoglu M, Kaya A, Civelek E, Ozcan C, Cakir B, Akan A et al. Prevalence of confirmed immediate type drug hypersensitivity reactions among school children. *Pediatr Allergy Immunol* 2013;**24**:160–167.
2. Rebelo GE, Fonseca J, Araujo L, Demoly P. Drug allergy claims in children: from self-reporting to confirmed diagnosis. *Clin Exp Allergy* 2008;**38**:191–198.
3. Lange L, Koningsbruggen SV, Rietschel E. Questionnaire-based survey of lifetime-prevalence and character of allergic drug reactions in German children. *Pediatr Allergy Immunol* 2008;**19**:634–638.
4. Orhan F, Karakas T, Cakir M, Akkol N, Bahat E, Sonmez FM et al. Parental-reported drug allergy in 6- to 9-yr-old urban schoolchildren. *Pediatr Allergy Immunol* 2008;**19**:82–85.
5. Tan VA, Gerez IF, Van Bever HP. Prevalence of drug allergy in Singaporean

- children. *Singapore Med J* 2009;**50**:1158–1161.
6. Star K, Noren GN, Nordin K, Edwards IR. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase. *Drug Saf* 2011;**34**:415–428.
7. Munoz MJ, Ayani I, Rodriguez-Sasiain JM, Gutierrez G, Aguirre C. Adverse drug reaction surveillance in pediatric and adult patients in an emergency room. *Med Clin (Barc)* 1998;**111**:92–98.
8. Gamboa PM. The epidemiology of drug allergy-related consultations in Spanish Allergology services: Alergologica-2005. *J Investig Allergol Clin Immunol* 2009;**19** (Suppl 2):45–50.
9. Vega AT, Gil CM, Rodriguez Recio MJ, de la Serna HP. [Incidence and clinical characteristics of maculopapular exanthemas of viral aetiology]. *Aten Primaria* 2003;**32**:517–523.
10. Ibia EO, Schwartz RH, Wiedermann BL. Antibiotic rashes in children: a survey in a private practice setting. *Arch Dermatol* 2000;**136**:849–854.
11. Scott LA, Stone MS. Viral exanthems. *Dermatol Online J* 2003;**9**:4.
12. Ramsay M, Reacher M, O'Flynn C, Buttery R, Hadden F, Cohen B et al. Causes of morbilliform rash in a highly immunised English population. *Arch Dis Child* 2002;**87**:202–206.
13. Caubet JC, Kaiser L, Lemaitre B, Fellay B, Gervais A, Eigenmann PA. The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. *J Allergy Clin Immunol* 2011;**127**:218–222.
14. Moral L, Garde J, Toral T, Fuentes MJ, Marco N. Short protocol for the study of paediatric patients with suspected betalactam antibiotic hypersensitivity and low risk criteria. *Allergol Immunopathol (Madr)* 2011;**39**:337–341.
15. Chambel M, Martins P, Silva I, Palma-Carlos S, Romeira AM, Leiria PP. Drug provocation tests to betalactam antibiotics: experience in a paediatric setting. *Allergol Immunopathol (Madr)* 2010;**38**:300–306.
16. Blanca-Lopez N, Zapatero L, Alonso E, Torres MJ, Fuentes V, Martinez-Molero MI et al. Skin testing and drug provocation in the diagnosis of nonimmediate reactions to aminopenicillins in children. *Allergy* 2009;**64**:229–233.
17. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S et al. Grading quality of evidence and strength of recommendations. *BMJ* 2004;**328**:1490.
18. International drug monitoring: the role of national centres. Report of a WHO meeting. *World Health Organ Tech Rep Ser.* 1972;**498**:1–25.
19. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. *J Allergy Clin Immunol* 2004;**113**:832–836.
20. Smyth RM, Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R et al. Adverse drug reactions in children—a systematic review. *PLoS One* 2012;**7**:e24061.
21. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. *Br J Clin Pharmacol* 2001;**52**:77–83.
22. Le J, Nguyen T, Law AV, Hodding J. Adverse drug reactions among children over a 10-year period. *Pediatrics* 2006;**118**:555–562.
23. Cohen AL, Budnitz DS, Weidenbach KN, Jernigan DB, Schroeder TJ, Shehab N et al. National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents. *J Pediatr* 2008;**152**:416–421.
24. Lee CE, Zembower TR, Fotis MA, Postelnick MJ, Greenberger PA, Peterson LR et al. The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. *Arch Intern Med* 2000;**160**:2819–2822.
25. Rubio M, Bousquet PJ, Gomes E, Romano A, Demoly P. Results of drug hypersensitivity evaluations in a large group of children and adults. *Clin Exp Allergy* 2012;**42**:123–130.
26. Macy E, Poon K-YT. Self-reported antibiotic allergy incidence and prevalence: age and sex effects. *Am J Med* 2009;**122**:778.
27. Hung OR, Bands C, Laney G, Drover D, Stevens S, MacSween M. Drug allergies in the surgical population. *Can J Anaesth* 1994;**41**:1149–1155.
28. Lieber NS, Ribeiro E. Adverse drug reactions leading children to the emergency department. *Rev Bras Epidemiol* 2012;**15**:265–274.
29. Rashed AN, Wong IC, Cranswick N, Tomlin S, Rascher W, Neubert A. Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study. *Eur J Clin Pharmacol* 2012;**68**:801–810.
30. Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher W et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. *Drug Saf* 2004;**27**:1059–1067.
31. Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. *Drug Saf* 2002;**25**:1–5.
32. Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. *Br J Clin Pharmacol* 2002;**54**:665–670.
33. Whitaker P, Naisbitt D, Peckham D. Non-immediate beta-lactam reactions in patients with cystic fibrosis. *Curr Opin Allergy Clin Immunol* 2012;**12**:369–375.
34. Matar R, Le Bourgeois M, Scheinmann P, de Blic J, Ponvert C. Beta-lactam hypersensitivity in children with cystic fibrosis: a study in a specialized pediatric center for cystic fibrosis and drug allergy. *Pediatr Allergy Immunol* 2014;**25**:88–93.
35. Mertes PM, Alla F, Trechot P, Auroy Y, Jouglu E. Anaphylaxis during anesthesia in France: an 8-year national survey. *J Allergy Clin Immunol* 2011;**128**:366–373.
36. Eshima N, Tokumaru O, Hara S, Bacal K, Korematsu S, Karukaya S et al. Age-specific sex-related differences in infections: a statistical analysis of national surveillance data in Japan. *PLoS One* 2012;**7**:e42261.
37. Ponvert C, Perrin Y, Bados-Albiero A, Le BM, Karila C, Delacourt C et al. Allergy to betalactam antibiotics in children: results of a 20-year study based on clinical history, skin and challenge tests. *Pediatr Allergy Immunol* 2011;**22**:411–418.
38. Heinzerling LM, Tomsitz D, Anliker MD. Is drug allergy less prevalent than previously assumed? A 5-year analysis. *Br J Dermatol* 2012;**166**:107–114.
39. Shiohara T, Kano Y. A complex interaction between drug allergy and viral infection. *Clin Rev Allergy Immunol* 2007;**33**:124–133.
40. Jappe U. Amoxicillin-induced exanthema in patients with infectious mononucleosis: allergy or transient immunostimulation? *Allergy* 2007;**62**:1474–1475.
41. Chovel-Sella A, Ben TA, Lahav E, Mor O, Rudich H, Paret G et al. Incidence of rash after amoxicillin treatment in children with infectious mononucleosis. *Pediatrics* 2013;**131**:e1424–e1427.
42. Hubiche T, Milpied B, Cazeau C, Taieb A, Leaute-Labreze C. Association of immunologically confirmed delayed drug reaction and human herpesvirus 6 viremia in a pediatric case of drug-induced hypersensitivity syndrome. *Dermatology* 2011;**222**:140–141.
43. Mardivirin L, Valeyrie-Allanore L, Brantal-Redon E, Beneton N, Jidar K, Barbaud A et al. Amoxicillin-induced flare in patients with DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on Human Herpesvirus 6 replication in vitro. *Eur J Dermatol* 2010;**20**:68–73.
44. Tohyama M, Hashimoto K, Yasukawa M, Kimura H, Horikawa T, Nakajima K et al.

- Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. *Br J Dermatol* 2007;**157**:934–940.
45. Ozcan D, Seckin D, Bilezikci B, Arslan H. The role of human herpesvirus-6, Epstein-Barr virus and cytomegalovirus infections in the etiopathogenesis of different types of cutaneous drug reactions. *Int J Dermatol* 2010;**49**:1250–1254.
46. Pirmohamed M, Park BK. HIV and drug allergy. *Curr Opin Allergy Clin Immunol* 2001;**1**:311–316.
47. Sanchez-Borges M, Capriles-Hulett A. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. *Ann Allergy Asthma Immunol* 2000;**84**:101–106.
48. Hassani A, Ponvert C, Karila C, Le BM, De BJ, Scheinmann P. Hypersensitivity to cyclooxygenase inhibitory drugs in children: a study of 164 cases. *Eur J Dermatol* 2008;**18**:561–565.
49. Quiralte J, Blanco C, Delgado J, Ortega N, Alcantara M, Castillo R et al. Challenge-based clinical patterns of 223 Spanish patients with nonsteroidal anti-inflammatory-drug-induced-reactions. *J Investig Allergol Clin Immunol* 2007;**17**:182–188.
50. Ponvert C, Scheinmann P. Allergic and pseudoallergic reactions to analgesics, antipyretics and non-steroidal anti-inflammatory drugs. *Arch Pediatr* 2007;**14**:507–512.
51. Kidon MI, Kang LW, Chin CW, Hoon LS, See Y, Goh A et al. Early presentation with angioedema and urticaria in cross-reactive hypersensitivity to nonsteroidal antiinflammatory drugs among young, Asian, atopic children. *Pediatrics* 2005;**116**:e675–e680.
52. Ayuso P, Blanca-Lopez N, Dona I, Torres MJ, Gueant-Rodriguez RM, Canto G et al. Advanced phenotyping in hypersensitivity drug reactions to NSAIDs. *Clin Exp Allergy* 2013;**43**:1097–1109.
53. Kidon MI, See Y. Adverse drug reactions in Singaporean children. *Singapore Med J* 2004;**45**:574–577.
54. Clavenna A, Bonati M. Drug prescriptions to outpatient children: a review of the literature. *Eur J Clin Pharmacol* 2009;**65**:749–755.
55. Rossignoli A, Clavenna A, Bonati M. Antibiotic prescription and prevalence rate in the outpatient paediatric population: analysis of surveys published during 2000–2005. *Eur J Clin Pharmacol* 2007;**63**:1099–1106.
56. Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. *Lancet* 2001;**357**:1851–1853.
57. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. *N Engl J Med* 1993;**328**:1670–1674.
58. Chanock SJ, Luginbuhl LM, McIntosh K, Lipshultz SE. Life-threatening reaction to trimethoprim/sulfamethoxazole in pediatric human immunodeficiency virus infection. *Pediatrics* 1994;**93**:519–521.
59. du Toit G, Reynolds L, Eley B. Induction of tolerance after a serious trimethoprim-sulphamethoxazole reaction in an HIV-infected child. *S Afr Med J* 2003;**93**:358–359.
60. Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. Ciprofloxacin safety in paediatrics: a systematic review. *Arch Dis Child* 2011;**96**:874–880.
61. Kurt E, Demir AU, Cadirci O, Yildirim H, Pinar ET. Immediate-type drug hypersensitivity and associated factors in a general population. *Allergol Immunopathol (Madr)* 2011;**39**:27–31.
62. Lesko SM, Mitchell AA. The safety of acetaminophen and ibuprofen among children younger than two years old. *Pediatrics* 1999;**104**:e39.
63. Settipane RA, Constantine HP, Settipane GA. Aspirin intolerance and recurrent urticaria in normal adults and children. Epidemiology and review. *Allergy* 1980;**35**:149–154.
64. Capriles-Behrens E, Caplin J, Sanchez-Borges M. NSAID facial angioedema in a selected pediatric atopic population. *J Investig Allergol Clin Immunol* 2000;**10**:277–279.
65. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. *BMJ* 2004;**328**:434.
66. Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A, Kelly JP et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. *Pediatrics* 2009;**123**:e297–e304.
67. Ferrandiz-Pulido C, Garcia-Patos V. A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. *Arch Dis Child* 2013;**98**:998–1003.
68. Dewachter P, Mouton-Faivre C. [Allergic risk during paediatric anaesthesia]. *Ann Fr Anesth Reanim* 2010;**29**:215–226.
69. Karila C, Brunet-Langot D, Labbez F, Jacquemarcq O, Ponvert C, Paupe J et al. Anaphylaxis during anesthesia: results of a 12-year survey at a French pediatric center. *Allergy* 2005;**60**:828–834.
70. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. *Radiology* 1990;**175**:621–628.
71. Callahan MJ, Poznauskis L, Zurakowski D, Taylor GA. Nonionic iodinated intravenous contrast material-related reactions: incidence in large urban children's hospital-retrospective analysis of data in 12,494 patients. *Radiology* 2009;**250**:674–681.
72. Dewachter P, Laroche D, Mouton-Faivre C, Bloch-Morot E, Cercueil JP, Metge L et al. Immediate reactions following iodinated contrast media injection: a study of 38 cases. *Eur J Radiol* 2011;**77**:495–501.
73. Wendt-Nordahl G, Rotert H, Trojan L, Michel MS, Peters CR, Alken P et al. Intravenous contrast media in uroradiology: evaluation of safety and tolerability in almost 50,000 patients. *Med Princ Pract* 2006;**15**:358–361.
74. Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC. Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults. *AJR Am J Roentgenol* 2007;**189**:1533–1538.
75. Li A, Wong CS, Wong MK, Lee CM, Au Yeung MC. Acute adverse reactions to magnetic resonance contrast media-gadolinium chelates. *Br J Radiol* 2006;**79**:368–371.
76. Prince MR, Zhang H, Zou Z, Staron RB, Brill PW. Incidence of immediate gadolinium contrast media reactions. *AJR Am J Roentgenol* 2011;**196**:W138–W143.
77. Yu DY, Dahl GV, Shames RS, Fisher PG. Weekly dosing of carboplatin increases risk of allergy in children. *J Pediatr Hematol Oncol* 2001;**23**:349–352.
78. Lafay-Cousin L, Sung L, Carret AS, Hukin J, Wilson B, Johnston DL et al. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience. *Cancer* 2008;**112**:892–899.
79. Schiavetti A, Varrasso G, Maurizi P, Castello MA. Hypersensitivity to carboplatin in children. *Med Pediatr Oncol* 1999;**32**:183–185.
80. Soyer OU, Aytac S, Tuncer A, Cetin M, Yetgin S, Sekerel BE. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia. *J Allergy Clin Immunol* 2009;**123**:895–899.
81. Kyonen LM, Folatre BI, Zolezzi RP, Badilla MV, Marin HF. [Adverse reactions to L-asparaginase in children with acute lymphatic leukemia]. *Rev Med Chil* 2006;**134**:1530–1534.
82. Kurtzberg J, Asselin B, Bernstein M, Buchanan GR, Pollock BH, Camitta BM. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866). *J Pediatr Hematol Oncol* 2011;**33**:610–616.

83. Pidaparti M, Bostrom B. Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly. *Pediatr Blood Cancer* 2012;**59**:436–439.
84. Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. *Br J Clin Pharmacol* 2011;**71**:684–700.
85. Ponvert C, Thong B. Epidemiology. In: Zitt J editor. ???, New York: Parthenon, 2014: ???–???
86. Segal AR, Doherty KM, Leggott J, Zlotoff B. Cutaneous reactions to drugs in children. *Pediatrics* 2007;**120**:e1082–e1096.
87. Sanchez-Borges M, Capriles-Behrens E, Caballero-Fonseca F. Hypersensitivity to non-steroidal anti-inflammatory drugs in childhood. *Pediatr Allergy Immunol* 2004;**15**:376–380.
88. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Risk of skin reactions when using ibuprofen-based medicines. *Expert Opin Drug Saf* 2005;**4**:837–848.
89. Kidon MI, Kang LW, Chin CW, Hoon LS, Hugo VB. Nonsteroidal anti-inflammatory drug hypersensitivity in preschool children. *Allergy Asthma Clin Immunol* 2007;**3**:114–122.
90. Khaled A, Kharfi M, Ben Hamida M, El Fekih N, El Aidli S, Zeglaoui F et al. Cutaneous adverse drug reactions in children. A series of 90 cases. *Tunis Med* 2012;**90**:45–50.
91. Morelli JG, Tay YK, Rogers M, Halbert A, Krafchik B, Weston WL. Fixed drug eruptions in children. *J Pediatr* 1999;**134**:365–367.
92. Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L et al. The DRESS syndrome: a literature review. *Am J Med* 2011;**124**:588–597.
93. Verrotti A, Trotta D, Salladini C, Chiarelli F. Anticonvulsant hypersensitivity syndrome in children: incidence, prevention and management. *CNS Drugs* 2002;**16**:197–205.
94. Dewan AK, Quinonez RA. Allopurinol-induced DRESS syndrome in an adolescent patient. *Pediatr Dermatol* 2010;**27**:270–273.
95. Vinson AE, Dufort EM, Willis MD, Eberson CP, Harwell JI. Drug rash, eosinophilia, and systemic symptoms syndrome: two pediatric cases demonstrating the range of severity in presentation – a case of vancomycin-induced drug hypersensitivity mimicking toxic shock syndrome and a milder case induced by minocycline. *Pediatr Crit Care Med* 2010;**11**:e38–e43.
96. Kawakami T, Fujita A, Takeuchi S, Muto S, Soma Y. Drug-induced hypersensitivity syndrome: drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki disease. *J Am Acad Dermatol* 2009;**60**:146–149.
97. Ozmen S, Misirlioglu ED, Gurkan A, Arda N, Bostanci I. Is acute generalized exanthematous pustulosis an uncommon condition in childhood? *Allergy* 2010;**65**:1490–1492.
98. Riten K, Shahina Q, Jeannette J, Palma-Diaz MF. A severe case of acute generalized exanthematous pustulosis (AGEP) in a child after the administration of amoxicillin-clavulanic acid: brief report. *Pediatr Dermatol* 2009;**26**:623–625.
99. Sezer E, Sezer T, Koseoglu D, Filiz NO. Acute generalized exanthematous pustulosis in a child. *Pediatr Dermatol* 2007;**24**:93–95.
100. Belhadjali H, Ghannouchi N, Njim L, Mohamed M, Moussa A, Bayou F et al. Acute generalized exanthematous pustulosis induced by buprenorphine in an atopic girl. *Contact Dermatitis* 2008;**58**:247–248.
101. Miteva L, Kadurina M, Schwartz RA. Childhood acute generalized exanthematous pustulosis induced by oral ketoconazole. *Acta Dermatovenol Croat* 2010;**18**:267–270.
102. Haro-Gabaldon V, Sanchez-Sanchez-Vizcaino J, Ruiz-Avila P, Gutierrez-Fernandez J, Linares J, Naranjo-Sintes R. Acute generalized exanthematous pustulosis with cytomegalovirus infection. *Int J Dermatol* 1996;**35**:735–737.
103. Lim CS, Lim SL. Acute generalized exanthematous pustulosis associated with asymptomatic *Mycoplasma pneumoniae* infection. *Arch Dermatol* 2009;**145**:848–849.
104. Leuppi JD, Schnyder P, Hartmann K, Reinhart WH, Kuhn M. Drug-induced bronchospasm: analysis of 187 spontaneously reported cases. *Respiration* 2001;**68**:345–351.
105. Hompes S, Kohli A, Nemat K, Scherer K, Lange L, Rueff F et al. Provoking allergens and treatment of anaphylaxis in children and adolescents – data from the anaphylaxis registry of German-speaking countries. *Pediatr Allergy Immunol* 2011;**22**:568–574.
106. Ribeiro-Vaz I, Marques J, Demoly P, Polonia J, Gomes ER. Drug-induced anaphylaxis: a decade review of reporting to the Portuguese Pharmacovigilance Authority. *Eur J Clin Pharmacol* 2013;**69**:673–681.
107. Vial T, Pont J, Pham E, Rabilloud M, Descotes J. Cefaclor-associated serum sickness-like disease: eight cases and review of the literature. *Ann Pharmacother* 1992;**26**:910–914.
108. Heckbert SR, Stryker WS, Coltin KL, Manson JE, Platt R. Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population. *Am J Epidemiol* 1990;**132**:336–342.
109. Sanklecha MU. Cefaclor induced serum sickness like reaction. *Indian J Pediatr* 2002;**69**:921.
110. King BA, Geelhoed GC. Adverse skin and joint reactions associated with oral antibiotics in children: the role of cefaclor in serum sickness-like reactions. *J Paediatr Child Health* 2003;**39**:677–681.
111. Platt R, Dreis MW, Kennedy DL, Kuritsky JN. Serum sickness-like reactions to amoxicillin, cefaclor, cephalixin, and trimethoprim-sulfamethoxazole. *J Infect Dis* 1988;**158**:474–477.
112. Lowery N, Kearns GL, Young RA, Wheeler JG. Serum sickness-like reactions associated with cefprozil therapy. *J Pediatr* 1994;**125**:325–328.
113. Ponvert C, Le CL, De BJ, Le BM, Scheinmann P, Paupe J. Allergy to beta-lactam antibiotics in children. *Pediatrics* 1999;**104**:e45.
114. Demoly P, Kropf R, Bircher A, Pichler WJ. Drug hypersensitivity: questionnaire. EAACI interest group on drug hypersensitivity. *Allergy* 1999;**54**:999–1003.
115. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA et al. International consensus on drug allergy. *Allergy* 2014;**69**:420–437.
116. Pichichero ME, Pichichero DM. Diagnosis of penicillin, amoxicillin, and cephalosporin allergy: reliability of examination assessed by skin testing and oral challenge. *J Pediatr* 1998;**132**:137–143.
117. Atanaskovic-Markovic M, Velickovic TC, Gavrovic-Jankulovic M, Vuckovic O, Nestorovic B. Immediate allergic reactions to cephalosporins and penicillins and their cross-reactivity in children. *Pediatr Allergy Immunol* 2005;**16**:341–347.
118. Romano A, Gaeta F, Valluzzi RL, Alonzi C, Viola M, Bousquet PJ. Diagnosing hypersensitivity reactions to cephalosporins in children. *Pediatrics* 2008;**122**:521–527.
119. Atanaskovic-Markovic M, Gaeta F, Gavrovic-Jankulovic M, Cirkovic VT, Valluzzi RL, Romano A. Diagnosing multiple drug hypersensitivity in children. *Pediatr Allergy Immunol* 2012;**23**:785–791.
120. Mori F, Barni S, Pucci N, Rossi E, Azzari C, de Martino M et al. Sensitivity and specificity of skin tests in the diagnosis of clarithromycin allergy. *Ann Allergy Asthma Immunol* 2010;**104**:417–419.
121. Adegbi H, Atadokpede F, Sagbo G, Koudoukpo C, D'Almeida M, Teclessou J et al. [Drug eruptions in children in Cotonou, Benin]. *Mali Med* 2012;**27**:42–46.
122. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. *Allergy* 2002;**57**:45–51.
123. Ponvert C, Weilenmann C, Wassenberg J, Walecki P, Bourgeois ML, De BJ et al. Allergy to betalactam antibiotics in children:

- a prospective follow-up study in retreated children after negative responses in skin and challenge tests. *Allergy* 2007;**62**:42–46.
124. Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB et al. Skin test concentrations for systemically administered drugs – an ENDA/EAACI Drug Allergy Interest Group position paper. *Allergy* 2013;**68**:702–712.
125. Barbaud A, Goncalo M, Bruynzeel D, Bircher A. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. *Contact Dermatitis* 2001;**45**:321–328.
126. Marrs T, Fox AT, Lack G, du Toit G. The diagnosis and management of antibiotic allergy in children: systematic review to inform a contemporary approach. *Arch Dis Child* 2015;**100**:583–588.
127. du Toit G, Lloyd K, Sinnott L, Forster D, Austin M, Clark C et al. The RCPCH care pathway for children with drug allergies: an evidence and consensus based national approach. *Arch Dis Child* 2011;**96**(Suppl 2): i15–i18.
128. Dworzynski K, Arden-Jones M, Nasser S. Diagnosis and management of drug allergy in adults, children and young people: summary of NICE guidance. *BMJ* 2014;**349**: g4852.
129. Novembre E, Mori F, Pucci N, Bernardini R, Romano A. Cefaclor anaphylaxis in children. *Allergy* 2009;**64**:1233–1235.
130. Somech R, Weber EA, Lavi S. Evaluation of immediate allergic reactions to cephalosporins in non-penicillin-allergic patients. *Int Arch Allergy Immunol* 2009;**150**:205–209.
131. Blanca M, Romano A, Torres MJ, Fernandez J, Mayorga C, Rodriguez J et al. Update on the evaluation of hypersensitivity reactions to betalactams. *Allergy* 2009;**64**:183–193.
132. Torres MJ, Blanca M, Fernandez J, Romano A, Weck A, Aberer W et al. Diagnosis of immediate allergic reactions to betalactam antibiotics. *Allergy* 2003;**58**:961–972.
133. Romano A, Blanca M, Torres MJ, Bircher A, Aberer W, Brockow K et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. *Allergy* 2004;**59**:1153–1160.
134. Padial A, Antunez C, Blanca-Lopez N, Fernandez TD, Cornejo-Garcia JA, Mayorga C et al. Non-immediate reactions to beta-lactams: diagnostic value of skin testing and drug provocation test. *Clin Exp Allergy* 2008;**38**:822–828.
135. Mattheij M, de Vries E. A suspicion of antibiotic allergy in children is often incorrect. *J Allergy Clin Immunol* 2012;**129**:583–584.
136. Atanaskovic-Markovic M, Medjo B, Gavrovic-Jankulovic M, Cirkovic Velickovic T, Nikolic D, Nestorovic B. Stevens-Johnson syndrome and toxic epidermal necrolysis in children. *Pediatr Allergy Immunol* 2013;**24**:645–649.
137. Fontaine C, Mayorga C, Bousquet PJ, Arnoux B, Torres MJ, Blanca M et al. Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy. *Allergy* 2007;**62**:47–52.
138. Gomez E, Blanca-Lopez N, Torres MJ, Requena G, Rondon C, Canto G et al. Immunoglobulin E-mediated immediate allergic reactions to dipyrone: value of basophil activation test in the identification of patients. *Clin Exp Allergy* 2009;**39**:1217–1224.
139. Gamboa PM, Garcia-Aviles MC, Urrutia I, Antepara I, Esparza R, Sanz ML. Basophil activation and sulfidoleukotriene production in patients with immediate allergy to betalactam antibiotics and negative skin tests. *J Invest Allergol Clin Immunol* 2004;**14**:278–283.
140. Hausmann OV, Gentinetta T, Bridts CH, Ebo DG. The basophil activation test in immediate-type drug allergy. *Immunol Allergy Clin North Am* 2009;**29**:555–566.
141. Aranda A, Mayorga C, Ariza A, Dona I, Rosado A, Blanca-Lopez N et al. In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones. *Allergy* 2011;**66**:247–254.
142. Torres MJ, Padial A, Mayorga C, Fernandez T, Sanchez-Sabate E, Cornejo-Garcia JA et al. The diagnostic interpretation of basophil activation test in immediate allergic reactions to betalactams. *Clin Exp Allergy* 2004;**34**:1768–1775.
143. Chopra R, Roberts J, Warrington RJ. Severe delayed-onset hypersensitivity reactions to amoxicillin in children. *CMAJ* 1989;**140**:921–923.
144. Firket H, Leclercq-Foucort J, Geubelle F. A simplified procedure for the use of the “blast-like transformation” of lymphocytes in culture as a routine clinical test results in a group of allergic children. *Acta Allergol* 1971;**26**:191–199.
145. Iannetti P, Raucci U, Zuccaro P, Pacifici R. Lamotrigine hypersensitivity in childhood epilepsy. *Epilepsia* 1998;**39**:502–507.
146. Torres MJ, Corzo JL, Leyva L, Mayorga C, Garcia-Martin FJ, Antunez C et al. Differences in the immunological responses in drug- and virus-induced cutaneous reactions in children. *Blood Cells Mol Dis* 2003;**30**:124–131.
147. Rozieres A, Hennino A, Rodet K, Gutowski MC, Gunera-Saad N, Berard F et al. Detection and quantification of drug-specific T cells in penicillin allergy. *Allergy* 2009;**64**:534–542.
148. Porebski G, Pecaric-Petkovic T, Groux-Keller M, Bosak M, Kawabata TT, Pichler WJ. In vitro drug causality assessment in Stevens-Johnson syndrome – alternatives for lymphocyte transformation test. *Clin Exp Allergy* 2013;**43**:1027–1037.
149. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. *Allergy* 2003;**58**:854–863.
150. Na HR, Lee JM, Jung JW, Lee SY. Usefulness of drug provocation tests in children with a history of adverse drug reaction. *Korean J Pediatr* 2011;**54**:304–309.
151. Rodriguez-Alvarez M, Santos-Magadan S, Rodriguez-Jimenez B, Reig-Rincon de Arelano I, Vazquez-Cortes S, Martinez-Cocera C. Reproducibility of delayed-type reactions to betalactams. *Allergol Immunopathol (Madr)* 2008;**36**:201–204.
152. Atanaskovic-Markovic M. Educational case series: beta-lactam allergy and cross-reactivity. *Pediatr Allergy Immunol* 2011;**22**:770–775.
153. Hershkovich J, Broides A, Kirjner L, Smith H, Gorodischer R. Beta lactam allergy and resensitization in children with suspected beta lactam allergy. *Clin Exp Allergy* 2009;**39**:726–730.
154. Romano A, Quarantino D, Di Fonso M, Papa G, Venuti A, Gasbarrini G. A diagnostic protocol for evaluating nonimmediate reactions to aminopenicillins. *J Allergy Clin Immunol* 1999;**103**:1186–1190.
155. Hjortlund J, Mortz CG, Skov PS, Eller E, Poulsen JM, Borch JE et al. One-week oral challenge with penicillin in diagnosis of penicillin allergy. *Acta Derm Venereol* 2012;**92**:307–312.
156. Hjortlund J, Mortz CG, Skov PS, Bindslev-Jensen C. Diagnosis of penicillin allergy revisited: the value of case history, skin testing, specific IgE and prolonged challenge. *Allergy* 2013;**68**:1057–1064.
157. Demoly P, Romano A, Botelho C, Bousquet-Rouanet L, Gaeta F, Silva R et al. Determining the negative predictive value of provocation tests with beta-lactams. *Allergy* 2010;**65**:327–332.
158. Defrance C, Bousquet PJ, Demoly P. Evaluating the negative predictive value of provocation tests with nonsteroidal anti-inflammatory drugs. *Allergy* 2011;**66**:1410–1414.
159. Waton J, Pouget-Jasson C, Loos-Ayav C, Trechot P, Bursztejn AC, Schmutz JL et al. Drug re-challenges in cutaneous adverse drug reactions: information and effectiveness in the long-term management of patients. *Allergy* 2011;**66**:941–947.
160. Caubet JC, Eigenmann PA. Managing possible antibiotic allergy in children. *Curr Opin Infect Dis* 2012;**25**:279–285.

161. Martin-Munoz F, Moreno-Ancillo A, Dominguez-Noche C, Diaz-Pena JM, Garcia-Ara C, Boyano T et al. Evaluation of drug-related hypersensitivity reactions in children. *J Investig Allergol Clin Immunol* 1999;**9**:172–177.
162. Kamboj S, Yousef E, McGeady S, Hossain J. The prevalence of antibiotic skin test reactivity in a pediatric population. *Allergy Asthma Proc* 2011;**32**:99–105.
163. Seitz CS, Brocker EB, Trautmann A. Diagnosis of drug hypersensitivity in children and adolescents: discrepancy between physician-based assessment and results of testing. *Pediatr Allergy Immunol* 2011;**22**:405–410.
164. Langley JM, Halperin SA, Bortolussi R. History of penicillin allergy and referral for skin testing: evaluation of a pediatric penicillin allergy testing program. *Clin Invest Med* 2002;**25**:181–184.
165. de Groot H, Mulder WM. Clinical practice: drug desensitization in children. *Eur J Pediatr* 2010;**169**:1305–1309.
166. Cernadas JR. Desensitization to antibiotics in children. *Pediatr Allergy Immunol* 2013;**24**:3–9.